Sokol, Leonard L.Young, Michael J.Espay, Alberto J.Postuma, Ronald B.2016-07-142016Sokol, Leonard L., Michael J. Young, Alberto J. Espay, and Ronald B. Postuma. 2016. “Cautionary optimism: caffeine and Parkinson’s disease risk.” Journal of Clinical Movement Disorders 3 (1): 7. doi:10.1186/s40734-016-0037-8. http://dx.doi.org/10.1186/s40734-016-0037-8.2054-7072http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662145Most Parkinson’s disease (PD) patients present without known family history and without a diagnosed prodromal phase, underscoring the difficulty of employing primary (neuroprevention) and secondary (neuroprotection) preventions. In cases of monogenic forms, however, potential gene-carrying family members of a proband could engage in neuroprevention, such as exercise or diet modifications, to attenuate the risk of, or delay, disease development. However, a historical lack of recognized disease-modifying interventions has limited clinicians’ ability to recommend reliable preventive measures in caring for at-risk populations. We briefly analyze the first retrospective study to examine caffeine consumption and PD risk in a LRRK2 R1628P cohort.en-USParkinson’s diseaseLRRK2CaffeineRisk factorsJournal Article2016-07-1410.1186/s40734-016-0037-8